Table of Contents Author Guidelines Submit a Manuscript
BioMed Research International
Volume 2017 (2017), Article ID 3521481, 6 pages
Research Article

In Vivo Murine Model of Leukemia Cell-Induced Spinal Bone Destruction

1Institute of Molecular Medicine, Health Science Center, Shenzhen University, Shenzhen 518060, China
2Vaccine Research Institute of Sun Yat-sen University, The Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China
3Department of Spine Surgery and Joint Surgery, The Third Affiliated Hospital of Guangzhou Medical University, Guangzhou 510150, China

Correspondence should be addressed to Jia-Jie Chen and Gang Chang

Received 23 April 2017; Revised 6 August 2017; Accepted 15 August 2017; Published 28 September 2017

Academic Editor: Peter J. Oefner

Copyright © 2017 Jia-Jie Chen et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.


Osteolytic bone lesions can be a consequence of leukemic bone infiltration or focal bone destruction by inflammatory factors released from leukemic cells. Destructive bone lesions have a negative impact on the quality of life of leukemia patients, causing unbearable pain and, in some cases, limb paralysis. However, the mechanism, by which leukemic cells produce destructive bone lesions, and the effect of therapeutics on osteolytic lesions have not been fully elucidated yet and, thus, stand to benefit from an in vivo model. To that end, HL-60 cells were transformed by retrovirus-mediated constitutively active (CA) STAT5 expression and injected into nonobese diabetic (NOD)/SCID mice via the tail vein. After three weeks, lumbar spines were subjected to histocytometric analysis. Xenograft mice developed hind limb paralysis in 2-3 weeks, which was consistent with the consequences of spinal bone destruction by extramedullary invasion of leukemia cells. The in vivo model will improve the understanding and treatment of osteolytic bone lesions caused by myeloid leukemic cells.